Úvod Laboratorní plasty Zkumavky Microcentrifuge Tube 1.5 ml Microcentrifuge Tube SALSA MLPA P377 Hematologic malign. probemix - 100 reactions

SALSA MLPA P377 Hematologic malign. probemix - 100 reactions

SALSA MLPA P377 Hematologic malign. probemix - 100 reactions

Hematological malignancies, various. Detailní informace

Cena s DPH € 1 147.08
Cena bez DPH € 948.00
 100 react
Dostupnost Skladem
Kód produktu P377-100R

Nejnovější informace o produktu naleznete exklusivně na stránkách výrobce MRC-Holland www.mlpa.com (nové okno)

Detailní popis SALSA MLPA P377 Hematologic malign. probemix - 100 reactions

P377-025R SALSA MLPA P377 Hematologic Malignancies probemix – 100 rxn

The P377-A1 MLPA probemix is intended for screening DNA samples derived from blood or bone marrow for the most common and diagnostically significant copy number changes associated with hematologic malignancies, including acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic lymphoid leukaemia (CLL), chronic myeloid leukaemia (CML), myelodysplastic syndrome (MDS) and various lymphomas. This kit is intended to be used in combination with karyotype analysis. Suggestions on MLPA probemixes that can be used to confirm results or to get a better resolution on genes or chromosomal areas of interest can be found in Table 2.

The P377-A1 probemix contains probes for several genes and chromosomal regions known to have a diagnostic or prognostic significant role in hematologic malignancies: 2p (MYCN and ALK), 5q (MIR145, EBF1 and MIR146A), 6q, 7p12 (IKZF1), 7q, 8q24 (MYC), 9p (JAK2 V617F mutation, MTAP, CDKN2A, CDKN2B and PAX5), 10q23 (PTEN), 11q23 (ATM), 12p (ETV6), 12q, 13q (RB1, MIR15A, DLEU2, DLEU1), 17p (TP53), 17q, Chr 18 and Chr 19, 21q (RUNX1).

This SALSA® MLPA® probemix is designed to detect copy number changes of one or more sequences in the above mentioned genes and chromosomal regions and to detect the presence of the aforementioned point mutation (JAK2 V617F) in a DNA sample. Heterozygous deletions of recognition sequences should give a 35-50% reduced relative peak area of the amplification product of that probe. Note that a mutation or polymorphism in the sequence detected by a probe can also cause a reduction in relative peak area, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions, duplications and amplifications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings.

Kontaktujte nás

Ke sv. Izidoru 2293/4A
140 00 PRAHA 4

Tel.: +420 241 401 693
Fax: +420 241 401 694
E-mail: biogen@biogen.cz

Novinky na e-mail

Vaše osobní údaje nejsou nikde zveřejňovány a splňují požadavky GDPR.